Cerebrospinal Fluid Markers in Sporadic Creutzfeldt-Jakob Disease

Sporadic Creutzfeldt-Jakob disease (sCJD) is the commonest form of human prion diseases, accounting for about 85% of all cases. Current criteria for intra vitam diagnosis include a distinct phenotype, periodic sharp and slow-wave complexes at electroencephalography (EEG), and a positive 14-3-3-protein assay in the cerebrospinal fluid (CSF). In sCJD, the disease phenotype may vary, depending upon the genotype at codon 129 of the prion protein gene (PRNP), a site of a common methionine/valine polymorphism, and two distinct conformers of the pathological prion protein. Based on the combination of these molecular determinants, six different sCJD subtypes are recognized, each with distinctive clinical and pathologic phenotypes. We analyzed CSF samples from 127 subjects with definite sCJD to assess the diagnostic value of 14-3-3 protein, total tau protein, phosphorylated181 tau, and amyloid beta (Aβ) peptide 1-42, either alone or in combination. While the 14-3-3 assay and tau protein levels were the most sensitive indicators of sCJD, the highest sensitivity, specificity and positive predictive value were obtained when all the above markers were combined. The latter approach also allowed a reliable differential diagnosis with other neurodegenerative dementias.

[1]  J. Chapman,et al.  Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel , 2011, Journal of Neurology.

[2]  W. Zhou,et al.  Elevated Levels of Tau Protein in Cerebrospinal Fluid of Patients With Probable Creutzfeldt-Jakob Disease , 2010, The American journal of the medical sciences.

[3]  A. Green,et al.  The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt–Jakob disease in the UK: a 10-year review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  H. Kretzschmar,et al.  14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes , 2009, Neurobiology of Aging.

[5]  C. Begue,et al.  Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease , 2009, Brain : a journal of neurology.

[6]  B. Hemmer,et al.  EFNS guidelines on disease‐specific CSF investigations , 2009, European journal of neurology.

[7]  A. Green,et al.  The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt–Jakob disease , 2009, Neuroscience Letters.

[8]  I. Santana,et al.  Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients , 2009, Journal of Neurology.

[9]  R. Petersen,et al.  Rapidly progressive neurodegenerative dementias. , 2009, Archives of neurology.

[10]  B. Miller,et al.  Rapidly Progressive Dementia , 2016, Continuum.

[11]  K. Hess,et al.  CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies , 2007, European journal of neurology.

[12]  H. Monaco,et al.  Detection of CSF 14-3-3 protein in Guillain–Barré syndrome , 2006, Neurology.

[13]  K. Hess,et al.  CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease , 2006, Neurology.

[14]  G. Zanusso,et al.  Cerebral amyloidoses: molecular pathways and therapeutic challenges. , 2006, Current medicinal chemistry.

[15]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[16]  G. Zanusso,et al.  Molecular mechanisms of human prion diseases , 2005 .

[17]  H. Monaco,et al.  Phosphorylated 14-3-3ζ protein in the CSF of neuroleptic-treated patients , 2005, Neurology.

[18]  Jennifer Farmer,et al.  Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.

[19]  P. Righetti,et al.  Identification of Distinct N-terminal Truncated Forms of Prion Protein in Different Creutzfeldt-Jakob Disease Subtypes* , 2004, Journal of Biological Chemistry.

[20]  R. Castellani,et al.  Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease , 2004, Neurology.

[21]  J. Martín,et al.  A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[22]  H. Vanderstichele,et al.  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias , 2003, Molecular Psychiatry.

[23]  J. Wiltfang,et al.  Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.

[24]  H. Budka,et al.  Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.

[25]  J. Kornhuber,et al.  Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.

[26]  C. Gibbs,et al.  The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. , 1996, The New England journal of medicine.

[27]  J Q Trojanowski,et al.  Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease , 1996, Annals of neurology.